Inpharma

Improved memory with AL 108 in mild cognitive impairment
pp. 1-1(1)

The latest gossip on physician-pharmaceutical industry affairs
pp. 2-2(1)

Storm in a teacup? More to come on the SEAS study at ESC
pp. 3-3(1)

Babes in the wood: recruitment of neonates to clinical trials
pp. 4-4(1)

While therapeutic HIV vaccines remain at an early stage, they may have a potential role to play
pp. 4-4(1)

Tocilizumab expected to find favour with US rheumatologists
pp. 4-4(1)

HPV vax likely to be worth it for 12-year-old girls in the UK
pp. 5-5(1)

Heads up on botulinum toxin's use in migraine
pp. 5-5(1)

Superior QOL with sunitinib in renal cancer
pp. 5-5(1)

Dimebolin may pay dividends in AD
pp. 6-6(1)

The lead product from a new class of agents named Altered Energy Metabolism Directed (AEMD) compounds has been approved by the US FDA for evaluation
pp. 6-6(1)

Rilpivirine in for the long haul in HIV treatment
pp. 7-8(2)

The immunotherapeutic vaccine CAD 106 for use in Alzheimer's disease
pp. 8-8(1)

CX 717 promising for opioid-induced respiratory depression
pp. 8-8(1)

ALTU 135 gives CF patients a fat chance
pp. 8-8(1)

Mind blowing results for tau aggregation inhibitor in Alzheimer's
pp. 9-10(2)

Enrolment has been completed in a phase III study evaluating salmon calcitonin for vertebral fractures in postmenopausal women.
pp. 10-10(1)

A phase Ia trial of the peripherally acting κ opioid agonist CR 845 has successfully been completed.
pp. 10-10(1)

Antihypertensives ease the pressure of cognitive impairment
pp. 11-11(1)

Sublingual immunotherapy (SLIT) using honeybee venom extract significantly reduces the extent of large local reactions
pp. 11-11(1)

Novel hepatitis B vaccine more than a match for standard
pp. 11-11(1)

PBT 2 impacts Aβ in Alzheimer's disease
pp. 12-12(1)

Bapineuzumab shows promise in Alzheimer's disease
pp. 12-12(1)

HE 3286 to be evaluated in phase I/II trial of patients with RA
pp. 12-12(1)

Clarifying the future of HIV vaccines and microbicides
pp. 13-14(2)

Enrolment has commenced for a new phase I trial evaluating the combination of AE 37 and another HER-2/neu-based cancer vaccine
pp. 14-14(1)

Inhaled mannitol [Bronchitol] has been shown to have a positive effect in patients with cystic fibrosis
pp. 14-14(1)

New research has been published on RNA interference (RNAi)-mediated silencing of a genetically validated regulator of LDL metabolism.
pp. 14-14(1)

You can forget about tarenflurbil for Alzheimer's disease
pp. 15-15(1)

Statin use may decrease risk of Alzheimer's disease
pp. 15-15(1)

Oral insulin spray to be assessed for ability to delay diabetes
pp. 15-15(1)

Kids show greater placebo response than adults
pp. 16-16(1)

Satavaptan improves ascites control in patients with cirrhosis
pp. 16-16(1)

Novel pain therapies: more than one-fifth market share by 2023
pp. 16-16(1)

A novel antiviral [HIVCide-I] being developed by Nanoviricides has shown a greater ability to reduce viral load than a standard anti-HIV cocktail
pp. 16-16(1)

Raltegravir rewards reinforced in ART-naive HIV-1 infections
pp. 17-17(1)

Doxorubicin plus docetaxel is as effective as doxorubicin plus cyclophosphamide for the treatment of operable breast cancer
pp. 17-17(1)

Lifestyle changes can reduce serum low-density lipoprotein cholesterol (LDL-C) levels in proportions similar to conventional simvastatin therapy
pp. 17-17(1)

Patients with sciatic pain appear to respond better to thioctic acid than to levacecarnine
pp. 18-18(1)

Atypical antipsychotics achieve modest symptom effects in AD
pp. 18-18(1)

Giving artesunate and amodiaquine in combination reduces total drug exposure to both drugs
pp. 18-18(1)

Adalimumab improves QOL in AS patients
pp. 18-18(1)

Comprehensive approach for extensively-drug resistant TB
pp. 19-19(1)

Boosted PI-based first-line HAART leads to less resistance
pp. 19-19(1)

Low-to-moderate dosages of topiramate as monotherapy are well tolerated and effective in elderly patients
pp. 19-19(1)

Male hormonal contraception: close but no cigar
pp. 20-20(1)

Rimonabant realises results for the rotund in RIO-Europe
pp. 20-20(1)

Orthokine therapy is a safe and effective treatment for knee osteoarthritis (OA), even after 2 years
pp. 20-20(1)

Famciclovir equivalent to valaciclovir in genital herpes
pp. 21-21(1)

Results ATTEST to the efficacy of abatacept and infliximab in RA
pp. 21-21(1)

A[torva]statin to the rescue again: this time in CKD
pp. 21-21(1)

Rituximab long-term efficacy for follicular lymphoma confirmed
pp. 22-22(1)

Tolterodine ER and tamsulosin team up to take on LUTS
pp. 22-22(1)

Phentolamine is efficacious and well tolerated as a local dental anaesthetic reversal agent
pp. 22-22(1)